Christian Schenk is an experienced investment director at Apposite Capital since November 2020, focusing on healthcare and life science companies, providing both capital and strategic guidance to management teams. In addition to this role, Christian serves as a non-executive director at Kelso Pharma and a board observer for Summit Medical Group Ltd and Emblation, all part of the Apposite Capital portfolio. Previously, Christian was an engagement manager at L.E.K. Consulting specializing in life sciences from September 2014 to November 2020, and a medical sales representative at Eli Lilly from November 2011 to February 2014. Earlier experience includes working as a vaccine scientist at Valneva and as a research scientist at the Research Institute of Molecular Pathology. Christian holds a Master of Science in Molecular Biology from the University of Vienna and has completed CFA Level 1 and 2.
This person is not in any teams
This person is not in any offices
Emblation
Emblation is a global leader in medical microwave technology, with a focus on radical innovation in the treatment of HPV infections, dermatology, cardiology, and oncology. Swift® – Award-winning treatments in Podiatry and Dermatology Launched in 2016, Swift® is one of the fastest growing treatments in Podiatry today - now available in the UK, Canada, Australia, and the USA. Find out more by visiting www.treatwithswift.com. Rapid Product Development Service (www.emblationmicrowave.com) Are you interested in using our platform for your clinical applications? We partner with carefully chosen global healthcare leaders to create best-in-class products using our patented microwave generator platform technology. Our partners can take advantage of a rapid product development capability, an agile and responsive team, and the potential for a streamlined regulatory submission – resulting in a significantly faster time to market.